It's the same process that you go through, generic or innovative. About 78% by volume is generic. The majority of the medicines are generics. It's only some that we're aware of that have the rebate system, which I'm sure Matthew touched on.
You go through the same system. Obviously the cost-utility analysis that PTAC does for Pharmac comes a little bit more into focus as a result, because innovative medicines cost a little bit more.
It's the same prices, essentially, but we have a lot less innovative medicines than a lot of other countries.